Case Study

Accelerating Treg Therapy Manufacturing

Source: ElevateBio
Lab Plates GettyImages-520238063

A group of industry experts and scientific pioneers wanted to bring an entirely new approach to the treatment of autoimmune disease and needed to develop a robust regulatory T cell (Treg) manufacturing process to support clinical development needs for a Treg cell therapy product with tissue-specific activation. The sponsor sought a strategic partner who could help accelerate the manufacturing development of Abata’s Treg cell therapies by offering high-quality process and analytical development, manufacturing capabilities, and technical expertise.

ElevateBio was able to serve as the sponsor’s CMC manufacturing partner from end to end. The partnership and strategy were capital efficient, and the ability to develop a novel baseline manufacturing process in ten months shaved approximately one year off the initial IND timeline for ABA-101. Learn more about the strategies that helped accelerate the development timeline and build a process to isolate, engineer, and expand mature, thymic Tregs.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma